Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies.
Anti-EGF receptor (EGFR) antibodies (cetuximab and panitumumab) have been demonstrated to be efficient in the treatment of metastatic colorectal cancer. However, these costly and potentially toxic treatments are active in a subset of patients, which renders necessary the identification of factors that are able to better define which patients will benefit from these treatments. Advances in the understanding of signaling pathways inhibited by these targeted therapies led to the identification of KRAS mutations as a strong predictor of resistance to anti-EGFR therapies. Other molecular markers, which are involved in the EGF signaling pathway or in the antibody dependent cell-mediated cytotoxicity-related anti-tumor effect of these anti-EGFR therapies, are also interesting and will have to be evaluated in future clinical trials.